Case Report: NUDT15 Polymorphism and Severe Azathioprine-Induced Myelosuppression in a Young Chinese Female with Systemic Lupus Erythematosus: A Case Analysis and Literature Review

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

The user has been managing hair loss for over 15 years, using treatments like Minoxidil, Finasteride, and corticosteroids, while experiencing side effects and recurrent Alopecia Areata. They seek advice on progression and potential underlying conditions, questioning if their hair loss is due to an autoimmune issue beyond typical patterns.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.